UC San Diego
SCHOOL OF MEDICINE
Shiley-Marcos Alzheimer's Disease Research Center

Altman Clinical and Translational Research Institute
9500 Gilman Drive, MC 0949, La Jolla CA 92093-0949
Telephone: 858-822-4800 (ADRC main)
clinicaltrialsADRC@ucsd.edu

Studies	Janssen JNJ-63733657ALZ2002	VIVA-MIND	Alnylam ALN-APP-001	AVANIR ASPECT AVP-786	Alector AL001-3
Required Diagnosis	Prodromal/Early **Alzheimer's Disease**	MCI due to Alzheimer's Disease, or mild probable **Alzheimer's Disease**	MCI or AD due to **early onset AD** (disease onset age <65, **amyloid positive**)	Probable **Alzheimer's Disease & Clinically significant, moderate-to-severe agitation**	**Frontotemporal Dementia** and **heterozygous loss-of-function progranulin gene (GRN) mutations**
Phase	2	2A/2B	1	3	3
Route of Therapy Administration	Infusion	Oral tablet	Intrathecal injection	Oral tablet	Infusion
Age	55 - 80 (inclusive)	50 – 89 (inclusive)	18 and older	50 - 90 (inclusive)	25 - 85 (inclusive)
Length	Up to 5 years	Min. of 24 wks for phase 2A. Phase 2B is planned to follow	Up to 14 months (Part A) Up to 24 months (Part B)	Up to 14 weeks	Up to 27 months Open Label Extension optional
Lumbar Puncture	Optional	Yes	10+ times	No	Optional
MRI	Required	Required	Required	No	Required
Amyloid PET	No	No	Required	No	No
Tau PET	Required	No	Optional	No	No
Compensation	Yes	Yes	Yes	Yes	Yes
Read more on clinicaltrials.gov	Identifier: NCT04619420	Identifier: NCT03919162	Identifier: NCT05231785	Identifier: NCT03393520	Identifier: NCT04374136

Required for all drug studies: Must have a study partner; No recent changes in AD medications or doses; No history of medical conditions other than the required diagnosis (e.g., AD, FTD) that could account for cognitive deficits.

FOR ALL STUDIES, PLEASE CONTACT clinicaltrialsADRC@ucsd.edu for more details